A Wnt/β-catenin pathway agonist under development by Surrozen appears to be effective against idiopathic pulmonary fibrosis (IPF) in mouse models, according to new data. The results, published April 2 ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

A pair of USC Stem Cell mouse studies detail how progenitor cells self-renew, differentiate, and aggregate into early kidney structures, offering insights for the creation of stem cell-based ...

Researchers at the Cancer Research Institute and the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have uncovered a critical mechanism that enables gastric cancer to spread to ...

Sclerosteosis arises from mutations in the SOST gene, causing abnormally high bone mass and skeletal overgrowth, which can lead to severe health issues such as hearing loss and increased intracranial ...

A new study reveals why some pancreatic and colorectal tumors resist targeted anti-Wnt drugs and suggests how to overcome it, offering new hope to patients with fully treatment-resistant cancers.

Gastric (stomach) cancer remains one of the most common and deadly cancers in East Asia, including Korea. Yet despite its high prevalence, it has received far less molecular attention than colorectal ...

Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for ...

Merck MRK announced that it started the phase IIb/III BRUNELLO study on Restoret (MK-3000), a novel investigational Wnt agonist antibody, to treat diabetic macular edema (DME). This study will ...

Nearly 60–70% of SCLC patients present with extensive-stage disease at diagnosis. Despite the availability of approved second-line agents, real-world data indicate that only 40% receive second-line ...